Clinical Trials Logo

HRD clinical trials

View clinical trials related to HRD.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05069818 Not yet recruiting - Ovarian Cancer Clinical Trials

Variance of HRD From Paired Ovarian Cancer

HOPEII
Start date: October 2021
Phase:
Study type: Observational

Homologous recombination deficiency (HRD) is an important biomarker of poly (ADP-ribose) polymerase inhibitor (PARPi) in patients with high-grade serous ovarian cancer (HGSOC). The stability of HRD in the recurrent HGSOC and its primary pair remains unknown.

NCT ID: NCT05044091 Not yet recruiting - Ovarian Cancer Clinical Trials

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

HOPEI
Start date: September 15, 2021
Phase:
Study type: Observational

Homologous recombination deficiency (HRD) is an important molecular biomarker for Poly (ADP-ribose) polymerase inhibitors (PARPi) which is a significant progress in the treatment of ovarian cancer. However, the proportion of HRD positive in real world and relationship of HRD status with PARPi in Chinese ovarian cancer patients remains unknown.